DMTs are expected to account for 73.5% of the global market. The global Alzheimer's disease (AD) market across the eight ...

The sleep aid Ambien could be allowing toxic proteins to pollute the brain, potentially increasing a person’s risk of ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Understanding dementia and Alzheimer’s disease is essential for maintaining a proactive approach to our well-being.

Gum disease appears to disrupt brain activity, potentially increasing a person’s risk of cognitive decline.People with ...

In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...

A new study reveals that the sleep aid Ambien (zolpidem) may increase Alzheimer’s risk by disrupting the brain's ...

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

“There are things that we can do at all stages of our lives deliberately,” says Prof Schott. “It’s never too early to start ...

The Tennessee Lady Volunteers are set to host its annual “We Back Pat” game at Food City Center on Thursday against ...